3M Pharmaceuticals, a division of 3M Health Care, develops, manufactures and sells branded prescription drug products related to dermatology, women’s health, sexual health, cardiology and respiratory medicine. 3M Pharmaceuticals is one of the fastest growing businesses at 3M with a strong portfolio of innovative products and a robust pipeline of future drugs.  Additional information is available at http://www.3m.com/us/healthcare/pharma/.           
                       
Immune Response Modifiers (IRMs) are a new class of drugs developed by 3M Pharmaceuticals.  IRMs work with the body's own immune system to fight diseased cells.  ALDARATM (imiquimod) cream, 5% is the first and only patient-applied topical IRM indicated for the treatment actinic keratosis, superficial basal cell carcinoma and external genital warts.                       
                       
3M Company is a $16 billion (US) diversified technology company with leading positions in industrial, consumer and office, health care, safety, electronics, telecommunications and other markets. The company has operations in more than 60 countries and serves customers in nearly 200 countries.                       
                       
3M Pharmaceuticals will continue to defend and grow its position in IRM science, establishing itself as a leader in dermatology.

Click here to close this window
and return to the Dermatology Update Sponsors Page.